NASDAQ:GTHX
G1 Therapeutics Inc Stock News
$4.25
-0.0200 (-0.468%)
At Close: May 07, 2024
Edited Transcript of GTHX.O earnings conference call or presentation 5-Nov-19 9:30pm GMT
02:44pm, Thursday, 21'st Nov 2019
Q3 2019 G1 Therapeutics Inc Earnings Call
G1 Therapeutics to Present at Stifel Healthcare Conference on November 19, 2019
12:00pm, Tuesday, 12'th Nov 2019
RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2019 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark.
We're Not Very Worried About G1 Therapeutics's (NASDAQ:GTHX) Cash Burn Rate
01:49pm, Friday, 08'th Nov 2019
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
3 Biotech Stocks Needham Expects to Double in the Next 12 Months
11:07am, Thursday, 07'th Nov 2019
Overall, the stock markets have been gaining in recent months. October saw a 2% bump for the general S&P; 500 index, as did the Dow Jones average. But not all market segments are created equal, and so
G1 Therapeutics Provides Third Quarter 2019 Corporate and Financial Update
09:00pm, Tuesday, 05'th Nov 2019
Company to complete New Drug Application (NDA) submission for trilaciclib in small cell lung cancer in 2Q20 Phase 2 trilaciclib data and Phase 1 G1T48 data presented at ESMO.
G1 Therapeutics to Provide Third Quarter Corporate and Financial Update on November 5, 2019
11:00am, Tuesday, 29'th Oct 2019
RESEARCH TRIANGLE PARK, N.C., Oct. 29, 2019 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and.
Stock Charts To Watch: ACHN, AKTX, DCPH, RKDA
12:00am, Friday, 16'th Aug 2019
Stocks Analysis by Harry Boxer covering: Nasdaq 100, S&P 500, US SmallCap 2000, iShares Russell 2000 ETF. Read Harry Boxer's latest article on Investing.com
G1 Therapeutics' trilaciclib joins the fight against breast cancer
04:00am, Thursday, 27'th Jun 2019
Breast cancer is one of the most common cancer types diagnosed in the world. One pharma company made a drug that helps beat it.
G1 Therapeutics, Inc. (GTHX), a clinical-stage oncology company, today announced preliminary overall survival (OS) results from a randomized Phase 2 trial which demonstrated that women with metastatic
